MARK LEJSEK: Open Payments
NPI 1891016010 · THE WOODLANDS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,240 in 134 payments from 17 companies in 2025. Trend: 2023 $2,853 · 2024 $2,589 · 2025 $2,240
Food & beverage: $2,240
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 23 | $421 |
| ABBVIE INC. | 28 | $385 |
| Tris Pharma Inc | 16 | $282 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $266 |
| Corium, LLC | 10 | $228 |
| Neos Therapeutics, LP | 20 | $187 |
| Bausch Health US, LLC | 4 | $83 |
| E.R. Squibb & Sons, L.L.C. | 4 | $76 |
| Otsuka America Pharmaceutical, Inc. | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $55 |
Products named: LYBALVI, VRAYLAR, CAPLYTA, Azstarys, Onyda XR, Adzenys XR-ODT, Dyanavel XR, APLENZIN.
Industry payments across TX — which companies pay providers there.
